The relative binding affinity of Zn2+ to several glycosaminoglycans was determined by gel-filtration chromatography. Binding was observed only between Zn2+ and heparin. No binding was observed between Zn2+ and chondroitin 4-sulphate, chondroitin 6-sulphate, dermatan sulphate or hyaluronic acid. All of the glycosaminoglycans contained carboxy groups, but only heparin bound Zn2+. This observation suggests that, contrary to a previously proposed hypothesis, simple electrostatic interactions between the negatively charged carboxy groups of the glycosaminoglycans and the positively charged Zn2+ cannot explain the observed binding.
Experimental evidence has shown that the normal prostate gland contains one of the highest concentrations of total zinc found in any organ or tissue in the human body (Mawson & Fischer, 1953) . In addition, good correlations between the total zinc concentration of the prostate or its secretions and the physiological state of the prostate have been reported [i.e. patients with prostatic carcinoma (Mawson & Fischer, 1952) and chronic bacterial prostatitis (Fair et al., 1976) demonstrate decreased contents of prostatic total zinc relative to that found in non-diseased prostatic tissue]. Although it has been established that Zn2+ complexed with a wide variety of natural and synthetic materials (Hughes, 1975) , only limited experimental results have been published about the chemical status of zinc in the prostate. A portion of the prostatic total zinc is known to be present as a coenzyme or cofactor in prostatic proteins (Vallee & Wacker, 1970 ) (e.g. carbonic anhydrase). A Zn2+-binding protein has been purified and partially characterized with respect to its molecular weight and amino acid composition (Reed & Stitch, 1973; Heathcote & Washington, 1973) , and expressed prostatic secretions contain complexes between Zn2+ and small peptides (Fair et al., 1976; Johnson et al., 1969) . Also, glycosaminoglycans (acid mucopolysaccharides) have been proposed as binding agents in vivo for prostatic Zn2+ (Sato & Gy6rkey, 1969 Fraction no.
Fig. 1. Elution profile ofheparinfrom Sephadex G-25
The column was equilibrated with 50mM-Hepes/ NaOH buffer, pH 7.0. A 1.0ml sample consisting of 5mg of heparin, dissolved in 5OmM-Hepes/NaOH buffer, pH 7.0, was applied to the column, and 35-drop fractions were collected. A 100/A sample was removed from each fraction and assayed for glycosaminoglycan content as indicated in the Experimental section. Fig. 3. matography, a new peak of zinc was observed (Fig.  3 ). This new peak of zinc corresponded to the heparin peak, indicating binding between heparin and Zn2+. Binding to a protein contaminant in the heparin preparation was eliminated by the observation that pretreatment of the heparin with pepsin, a broad-specificity proteinase, did not eliminate the binding of Zn2+ and heparin. Control experiments indicated that pepsin did not bind Zn2+.
To determine whether Zn2+ binding was a specific property of heparin or a general glycosaminoglycan effect, a series of glycosaminoglycans, previously shown to be present in human prostatic tissue (Sato & Gy6rkey, 1972) , was tested for Zn2+ binding under conditions identical with those previously utilized for heparin. The results presented in Table 1 showed that none of the other glycosaminoglycans exhibited any Zn2+ binding. It should be pointed out that it was necessary to dilute the heparin-containing fractions 41-fold in order to obtain satisfactory absorbance readings for the zinc determinations. However, when zinc concentrations were determined in the column fractions containing the other glycosaminoglycans, no dilution was made, and no zinc was detected in any fractions that contained glycosaminoglycan. This reinforces the selective nature of the Zn2+ binding by heparin relative to glycosaminoglycans previously demonstrated to be present in the prostate.
Discussion
The studies by Sato & Gyorkey (1969) and Gy6rkey & Sato (1968) (Sato & Gy6rkey, 1969) . In addition, when the formalin-fixed tissue was stained for glycosaminoglycan with Alcian Blue, the Zn2+ binding was found to be localized in the glycosaminoglycan-staining area (Gy6rkey & Sato, 1968) . It was later reported that dermatan sulphate and hyaluronic acid accounted for 62% and 25% of the isolatable glycosaminoglycans from human prostate. The remainder of the isolatable glycosaminoglycans were reported to be chondroitin 4-sulphate and chondroitin 6-sulphate in amounts of 11% and 2% respectively (Sato & Gyorkey, 1972 
